The Food and Drug Administration (FDA) has approved Romvimza â„¢ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback